Development of Biomarkers and Antineoplastic Drugs in Solid Tumors
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".
Deadline for manuscript submissions: 31 July 2025 | Viewed by 21
Special Issue Editors
Interests: melanoma; biomarkers; drugs; immunotherapy; digital
Interests: melanoma; immunotherapy; target therapy; biomarkers; drugs
Interests: genitourinary cancers; precision medicine; biomarkers
Special Issue Information
Dear Colleagues,
In recent decades, biomarkers’ discovery in oncology has run parallel to the development of novel antineoplastic agents.
Drug regulatory agencies have approved new compounds, combinations, or extensions of indications for already approved drugs. Clinicians have not abandoned chemotherapy but rather rejuvenated it by combining it with other agents (i.e., immunotherapy) or conjugating cytotoxic drugs to a monoclonal antibody. Immune checkpoint inhibitors, antibody–drug conjugates, and targeted agents have improved the survival outcomes of many patients suffering from different cancer types and modified toxicity profiles. Tumor-infiltrating lymphocyte cell therapy (TIL) and autologous vaccine therapy represent two pioneering examples of highly personalized treatments with unique properties for every patient.
Besides drug development, biomarkers play a crucial role in tumor diagnosis, predicting response to therapies, mechanisms of resistance, and prognosis. Tissues, fluid, and fecal samples represent the sources for biomarker identification. Gene signatures and cell-free DNA are routinely used in oncology practice to support clinicians in medical choices. Novel biomarkers (digital biomarkers, microbiome profiles, etc.) are currently under evaluation.
Dr. Rosa Falcone
Guest Editor
Dr. Sofia Verkhovskaia
Dr. Michela Roberto
Guest Editor Assistants
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- solid tumors
- drugs
- biomarkers
- immunotherapy
- targeted therapy
- artificial intelligence
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
